EDNRA and ovarian cancer: Of clinical relevance, in HG-SOC patients, which accounts for 70–80% of ovarian cancer deaths, an ETAR/ZEB1 signature is associated with poor prognosis, highlighting the worse outcomes generated by the integration between ETAR and ZEB1 transcriptional machinery for these patients still suffering from limited treatment option.